Investigational Drug Details
| Drug ID: | D385 |
| Drug Name: | Clenbuterol |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB01407 |
| DrugBank Description: | A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. |
| PubChem ID: | 2783 |
| CasNo: | 37148-27-9 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 |
| Structure: |
|
| InChiKey: | STJMRWALKKWQGH-UHFFFAOYSA-N |
| Molecular Weight: | 277.19 |
| DrugBank Targets: | Beta-2 adrenergic receptor; Beta-1 adrenergic receptor; Beta-3 adrenergic receptor; Beta-nerve growth factor; Tumor necrosis factor |
| DrugBank MoA: | Clenbuterol is a Beta(2) agonist similar in some structural respects to salbutamol. Agonism of the beta(2) receptor stimulates adenylyl cyclase activity which ultimately leads to downstream effects of smooth muscle relaxation in the bronchioles. |
| DrugBank Pharmacology: | Clenbuterol is a substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. Although approved for use in some countries, as of fall, 2006, clenbuterol is not an ingredient of any therapeutic drug approved by the U.S. Food and Drug Administration. |
| DrugBank Indication: | Used as a bronchodilator in the treatment of asthma patients. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|